By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Lysosomal Therapeutics 

19 Blackstone Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS

Lysosomal Therapeutics Inc. (LTI) is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Our strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish a unique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease and other synucleinopathies.

YEAR FOUNDED:

2014

LEADERSHIP:

Founders: Dimitri Krainc, Joseph Mazzulli, Henri Termeer, Peter Wirthand, Peter Wirth, Bob Carpenter, and Kees Been

Founder and CEO: Kees Been

CFO: Daniel Geffken

CSO: Peter Lansbury


Key Statistics


Email: Info@LysosomalTx.com
Ownership: Private

Web Site: Lysosomal Therapeutics
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
//-->